CPA Guidelines for the Pharmacological Treatment of Schizophrenia Spectrum and Other Psychotic Disorders in Children and Youth, Can. J. Psychiatry Rev. Can. Psychiatr, 2017. ,
Assessing depression in schizophrenia: the Calgary Depression Scale, Br. J. Psychiatry, pp.39-44, 1993. ,
Metabolic syndrome-a new worldwide definition. A Consensus Statement from the International Diabetes Federation, Diabet. Med, vol.23, pp.469-480, 2006. ,
Adjusting for multiple testing-when and how?, J. Clin. Epidemiol, vol.54, pp.343-349, 2001. ,
So depression is an inflammatory disease, but where does the inflammation come from, BMC Med, vol.11, 0200. ,
FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) Group, 2016. Chronic Peripheral Inflammation is Associated With Cognitive Impairment in Schizophrenia: Results From the Multicentric FACE-SZ Dataset ,
, , 2017.
, Polyunsaturated Fatty Acids as Augmentation Therapy in Treatment-Resistant Schizophrenia, Prim. Care Companion CNS Disord, vol.19
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies, Lancet Lond. Engl, vol.375, issue.10, pp.60484-60493, 2010. ,
C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications, Mol. Psychiatry, vol.21, pp.554-564, 2016. ,
Peripheral Immune Cell Populations Associated with Cognitive Deficits and Negative Symptoms of Treatment-Resistant Schizophrenia, PloS One, vol.11, 2016. ,
The promise of biological markers for treatment response in first-episode psychosis: a systematic review, Schizophr. Bull, vol.41, pp.559-573, 2015. ,
Effectiveness and tolerance of anti-inflammatory drugs' add-on therapy in major mental disorders: a systematic qualitative review, Acta Psychiatr. Scand, vol.129, pp.163-179, 2014. ,
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation, WFSBP Task Force on Treatment Guidelines for Schizophrenia, 2015. ,
, Soc. Biol. Psychiatry, vol.16, pp.142-170
National and international schizophrenia guidelines. Update 2013 regarding recommendations about antipsychotic pharmacotherapy, Nervenarzt, vol.84, pp.1366-1368, 2013. ,
C-reactive protein levels and treatment resistance in schizophrenia-A Danish population-based cohort study, Hum. Psychopharmacol, vol.32, 2017. ,
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology, Am. J. Psychiatry, vol.174, pp.216-229, 2017. ,
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology, Am. J. Psychiatry, vol.174, pp.216-229, 2017. ,
Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones, Prog. Neuropsychopharmacol. Biol. Psychiatry, vol.65, pp.34-48, 2016. ,
A significant causal association between C-reactive protein levels and schizophrenia, Sci. Rep, vol.6, 2016. ,
Clozapine for the treatmentresistant schizophrenic. A double-blind comparison with chlorpromazine, Arch. Gen. Psychiatry, vol.45, pp.789-796, 1988. ,
Effects of Electroconvulsive Therapy on Some Inflammatory Factors in Patients With Treatment-Resistant Schizophrenia, J. ECT, vol.32, pp.174-179, 2016. ,
The positive and negative syndrome scale (PANSS) for schizophrenia, Schizophr. Bull, vol.13, pp.261-276, 1987. ,
Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode, BMJ Open, vol.7, 2017. ,
Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment, Lancet Psychiatry, vol.2, issue.14, pp.122-131, 2015. ,
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis, Lancet Lond. Engl, vol.382, pp.60733-60736, 2013. ,
What does the PANSS mean?, Schizophr. Res, vol.79, pp.231-238, 2005. ,
The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics, Schizophr. Bull, vol.41, pp.549-558, 2015. ,
Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response, J. Clin. Psychiatry, vol.70, pp.990-996, 2009. ,
Recommendations for the optimal care of patients with recent-onset psychosis in the Asia-Pacific region, Asia-Pac. Psychiatry Off. J. Pac. Rim Coll. Psychiatr, vol.8, pp.154-171, 2016. ,
A review of peripheral biomarkers in major depression: The potential of inflammatory and oxidative stress biomarkers, Prog. Neuropsychopharmacol. Biol. Psychiatry, vol.48, pp.102-111, 2014. ,
Treatment-resistant schizophrenia--the role of clozapine, Curr. Med. Res. Opin, vol.14, pp.1-20, 1997. ,
, , 2004.
Cortisol and Inflammatory Biomarkers Predict Poor Treatment Response in First Episode Psychosis, Schizophr. Bull, vol.41, pp.1162-1170, 2015. ,
High serum soluble tumor necrosis factor receptor 1 predicts poor treatment response in acute-stage schizophrenia, Prog. Neuropsychopharmacol. Biol. Psychiatry, vol.76, pp.145-154, 2017. ,
Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials, Schizophr. Bull, vol.39, pp.1230-1241, 2013. ,
New evidence in support of staging approaches in schizophrenia: Differences in clinical profiles between first episode, early stage, and late stage, Compr. Psychiatry, vol.73, pp.93-96, 2017. ,
The evolving definition of treatment resistance, J. Clin. Psychiatry, vol.60, pp.4-8, 1999. ,
Effects of clozapine on plasma cytokine and soluble cytokine receptor levels, J. Clin. Psychopharmacol, vol.16, pp.403-409, 1996. ,
Guidelines for the Pharmacotherapy of Schizophrenia in Adults, Can. J. Psychiatry Rev. Can. Psychiatr, 2017. ,
N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: a double blind randomised placebo controlled trial targeting negative symptoms, BMC Psychiatry, vol.16, 2016. ,
, , 2013.
, L'Encephale, vol.39, pp.189-203
FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) collaborators, 2015. A National network of schizophrenia expert centres: An innovative tool to bridge the research-practice gap, Eur. Psychiatry J. Assoc. Eur. Psychiatr ,
Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis, Can. J. Psychiatry Rev. Can. Psychiatr, 2017. ,
Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update, Schizophr. Bull. sbt139, 2013. ,
Meta-guidelines" for the management of patients with schizophrenia, CNS Spectr, vol.18, pp.150-162, 2013. ,
The concurrent validity of the Global Assessment of Functioning (GAF), Br. J. Clin. Psychol, vol.41, pp.417-422, 2002. ,
Treatment resistance and other complicating factors in the management of schizophrenia, CNS Spectr, vol.19, issue.1, pp.16-23, 2014. ,
Evaluating the Effect of the Changes in FDA Guidelines for Clozapine Monitoring, J. Clin. Psychiatry, 2017. ,
Factors associated with response to clozapine in schizophrenia: a review, Psychopharmacol. Bull, vol.44, pp.32-60, 2011. ,
A rating scale for mania: reliability, validity and sensitivity, Br. J. Psychiatry, vol.133, pp.429-435, 1978. ,